Options: Show MedDRA Preferred Terms
Information about indications was extracted from the indications and usage sections of the labels.
Indication | Labels | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
Cardiac failure congestive | x | x | x | |||||||||||||
Cerebral artery embolism | x | x | x | |||||||||||||
Cerebrovascular accident | x | x | x | x | x | x | x | x | x | x | ||||||
Clotting | x | x | x | |||||||||||||
Embolism | x | x | x | x | x | |||||||||||
Genetic polymorphism | x | |||||||||||||||
Haemorrhage | x | |||||||||||||||
Hepatic function abnormal | x | |||||||||||||||
Hepatic impairment | x | |||||||||||||||
Increased anticoagulant effect | x | |||||||||||||||
Myocardial infarction | x | x | x | x | x | x | x | x | x | x | x | |||||
Pulmonary embolism | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
Renal failure | x | |||||||||||||||
Renal impairment | x | |||||||||||||||
Thromboembolic event | x | x | x | x | x | x | ||||||||||
Thromboembolism | x | |||||||||||||||
Thrombophlebitis | x | x | x | |||||||||||||
Thrombosis | x | |||||||||||||||
Venous thrombosis | x | x | x | x | x | x | x | x | x | x | x | x | x |
standard – alternative
100% | ||
75% | ||
50% | ||
10% | ||
frequent (1% to 100%) | ||
infrequent (0.1% to 1%) | ||
rare (<0.1%) | ||
postmarketing | ||
0% | ||
no frequency information | ||
not found on label |